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Background: Array CGH is widely used in cytogenetics centres for postnatal constitutional genome analysis, and is
now recommended as a first line test in place of G-banded chromosome analysis. At our centre, first line testing by
oligonucleotide array CGH for all constitutional referrals for genome imbalance has been in place since June 2008,
using a patient vs patient hybridisation strategy to minimise costs.
Findings: Out of a total of 13,412 patients tested with array CGH, 8,794 (66%) had array CGH as the first line test.
Referral indications for this first line group ranged from neonatal congenital anomalies through to adult
neurodisabilities; 25% of these patients had CNVs either in known pathogenic regions or in other regions where
imbalances have not been reported in the normal population. Of these CNVs, 46% were deletions or nullisomy,
53% were duplications or triplications, and mosaic imbalances made up the remainder; 87% were <5Mb and would
likely not be detected by G-banded chromosome analysis. For cases with completed inheritance studies, 20% of
imbalances were de novo.
Conclusions: Array CGH is a robust and cost-effective alternative to traditional cytogenetic methodology; it
provides a higher diagnostic detection rate than G-banded chromosome analysis, and adds to the sum of
information and understanding of the role of genomic imbalance in disease. Use of novel hybridisation strategies
can reduce costs, allowing more widespread testing.
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Array CGH (aCGH) has a much higher resolution than
G-banded chromosome analysis and most cytogenetic
departments are now using this approach either as an
adjunct to G-banded chromosome analysis, or as a first-
line test for selected patient groups [1,2]. The implemen-
tation of oligonucleotide aCGH at our centre has been
described in a previous paper [3]; this service has been
offered since May 2008 using a patient vs patient (pheno-
type mismatched) hybridisation strategy to minimise
costs, an important consideration in a state-funded health* Correspondence: joowook.ahn@nhs.net
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reproduction in any medium, provided the orservice; first line testing by aCGH for all constitutional
referrals for genome imbalance has been in place since
September 2008. We have now tested a total of 13,412
samples; here, we report on our findings for all samples
where aCGH was used as a first line test (n=8,794).Patients
Patients were referred from paediatric, neonatal and adult
disability populations within our NHS regional area
(population ~6M), and from other centres both in the UK
and abroad. The median age for the first line testing group
was 4 years (range: newborn - 78yrs); referrals were for de-
velopmental delay, more specific neurodisability (autism,
ADHD, etc.), congenital abnormalities, dysmorphism, or
other specific phenotypes (eg café au lait patches).. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Genomic DNA extracted from peripheral blood or
saliva, or DNA provided by external laboratories, was
processed as previously described [3]. Briefly, samples
were co-hybridised with other samples mismatched for
phenotype and matched for sex (thus halving consum-
able costs compared with patient vs control). Agilent
4x44k oligonucleotide array platform AMADID 017457
was initially used, replaced in 2010 by an 8x60k platform
(AMADID 028469) which included additional probes in
regions of clinical interest, and in the pseudoautosomal
regions. Analysis was performed using Agilent algorithm
ADM-2, threshold 6 and a 3-probe minimum aberration
call; a further analysis using ADM-1 was carried out to
maximise detection of mosaicism [4]. Imbalances of
regions represented in the Database of Genomic Variants
[5] in at least three non-BAC based studies were classi-
fied benign, and recorded but not reported. All samples
with other imbalances were re-tested using G-banded
karyotyping, QF-PCR, FISH, custom MLPA [6] or a
repeat array.
Turn-around times and success rates
The average reporting time for first-line tests over the
entire period was 21 days from receipt of sample.
Hybridisations that did not meet QC metric thresholds
(DLRS, % non-uniform outliers, signal intensity and signal
to noise) were repeated. Occasionally, it was not possible
to complete testing, usually due to DNA degradation. The
overall success rate was 99%.
Imbalances detected
Tables 1 and 2 show the imbalances detected in 8,794
patients tested by first line aCGH. All individuals with
features suggestive of Down, Edwards, Patau or Turner
syndrome were first tested with QF-PCR [7] and if posi-
tive did not proceed to aCGH; hence the prevalence of
these syndromes may appear lower in this patient group
than in other reports. 25% of patients had CNVs either
in known pathogenic regions or in other regions where
imbalances have not been reported in the normal popu-
lation. Of these CNVs, 46% were deletions or nullisomy,
53% were duplications or triplications, and mosaic im-
balances made up the remainder; 87% were <5Mb and
would likely not be detected by traditional karyotyping.
For cases with completed inheritance studies, 20% of im-
balances were de novo.
The most common findings in our dataset were imbal-
ance in the 22q11.2 deletion syndrome region (OMIM
188400, 192430, 608363; 83 cases), and deletion or du-
plication of the 16p11.2 autism susceptibility locus
(OMIM 611913, 614671; 60 cases). Size of imbalances
ranged from <25kb to whole chromosomes, with most
pathogenic, syndromic and susceptibility locus imbalancesbeing submicroscopic, whereas “private” imbalances ranged
from <25kb to 105Mb, (69% <5Mb). All these diagnostic
findings can be viewed on the UCSC Genome Browser via
http://bbgre.org.
Interpretation
The size of imbalances with potential clinical signifi-
cance generally correlated with severity of phenotype,
although there were exceptions. For instance, a ~7Mb
duplication (4p15.2p15.1(23,365,794-30,530,905)x3) was
found in two siblings, only one of whom had a clinical
phenotype. It therefore seems unlikely that the duplica-
tion alone was causative in the affected sibling. Towards
the other end of the size scale, a deletion of 157kb that
included part of SALL1 and no other genes was found in
an infant with microcephaly, ear tags and imperforate
anus; SALL1 mutation is associated with Townes-Brocks
syndrome (OMIM 107480), consistent with the referral
indication. These examples demonstrate the potential
pitfalls of using arbitrary size cut-offs and the need for
careful consideration of gene content of unbalanced
regions when interpreting aCGH data.
Inheritance studies
We were only able to complete inheritance studies for
50% of patients with imbalances; 20% had imbalances
that had arisen de novo. Inheritance patterns may be
considered key to clinical interpretation of aCGH find-
ings; however, it has become clear that simple rules can-
not be used [8]. For instance, of our de novo findings,
8% (21/226) did not appear to be associated with the
patient’s clinical features; some included no genes or
regulatory elements and were therefore unlikely to be
clinically significant. Detection of benign de novo CNVs
is unsurprising considering estimates for the de novo
CNV mutation rate in the normal population [9]. Con-
versely, at least 20% of inherited imbalances represented
susceptibility loci, and were therefore considered to be
clinically significant; the clinical status of the carrier par-
ent was generally not known. Penetrance of phenotype
associated with these susceptibility loci is often variable;
for instance, the 15q13.3 deletion syndrome imbalance
has been reported with different clinical presentations
within the same family [10].
Structural information
aCGH does not give information on the location in the
genome of, for instance, duplicated regions, or on the
structure of chromosomes. However, patterns of imbal-
ance can be used to deduce this information in some
cases; for instance, terminal deletion of one chromosome
with duplication of terminal material of another chromo-
some is indicative of a derivative chromosome, and G-
banded chromosome analysis and/or FISH for the parents
Table 1 Summary of findings from first line array CGH testing, June 2008 - Sept 2012
n %
TOTAL FIRST LINE PATIENTS 8,794
Abnormal 2,218 25% (of total patients)
Normal 6,576
Completed inheritance studies 1,111 50% (of abnormals)
De novo 226 20% (of completed inheritance)
Inherited 885 80% (of completed inheritance)
TOTAL IMBALANCES # 2,596
Deletions / nullisomy (all chromosomes) 1,182 46% (of all imbalances)
Deletions (autosomes) 1,102 42% (of all imbalances)
Nullisomy (autosomes) 8 <1% (of all imbalances)
Deletions / nullisomy (sex chromosomes) 72 3% (of all imbalances)
Duplications (all chromosomes) 1,240 48% (of all imbalances)
Duplications (autosomes) 951 37% (of all imbalances)
Duplications (sex chromosomes) 289 11% (of all imbalances)
Triplications (all chromosomes) 132 5% (of all imbalances)
Triplications (autosomes) 120 5% (of all imbalances)
Triplications (sex chromosomes) 12 <1% (of all imbalances)
Amplifications 1* <1% (of all imbalances)
Mosaics (all chromosomes) 41 2% (of all imbalances)
x0~1 5 <1% (of all imbalances)
x1~2 19 1% (of all imbalances)
x1~3 2 <1% (of all imbalances)
x2~3 13 1% (of all imbalances)
x2~4 2 <1% (of all imbalances)
Whole chromosome 79 3% (of all imbalances)
Whole chromosome mosaic 19 1% (of all imbalances)
Reduced copy number >=5Mb 74 3% (of all imbalances)
Reduced copy number <5Mb 1,108 43% (of all imbalances)
Increased copy number >=5Mb 86 3% (of all imbalances)
Increased copy number <5Mb 1,153 44% (of all imbalances)
PATHOGENIC IMBALANCES # 868 33% (of all imbalances)
Whole chromosome 79 9% (of pathogenic imbalances)
Syndromic imbalances 225 26% (of pathogenic imbalances)
Susceptibility loci 205 24% (of pathogenic imbalances)
Other pathogenic (private mutations) 359 41% (of pathogenic imbalances)
# Patients may carry more than one pathogenic imbalance.
* This patient carried 5 copies in total of a region of chromosome 7.
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duced (e.g. 5p15.33p14.1(148,243-27,385,955)x1,5p14.1p13.3
(27,463,381-31,329,932)x3), as can ring chromosomes (e.g.
18p11.32p11.21(170,229-14,918,854)x1~2,18q22.1q23(61,430,
694-76,083,117)x1~2), supernumerary ring chromosomes
(8p12q11.1(35,817,703-47,655,281)x2~3) and inversion
recombinants (e.g. 5p15.33p15.2(148,243-13,743,977)x1,5q35.2q35.3(172,591,725-180,617,107)x3). When aCGH is
used as the first line test, cultured material from patients
may not be available for immediate confirmation of any
suspected structural rearrangements by karyotyping or
FISH. The correct interpretation of array findings is there-
fore critical, as this will inform which follow-up studies
are most appropriate.
Table 2 Established genomic disorders detected
OMIM Syndrome n del (x1) dup (x3) trp (x4)
607872 1p36 2 2 - -
612474/612475 1q21.1 $ 42 20 22 -
600430 2q37 4 4 - -
609425/611936 3q29 8 2 6 -
194190 Wolf-Hirschhorn 2 2 - -
123450 Cri du Chat 3 3 - -
175100 Familial Adenomatous Polyposis 1 1 1 - -
117550 Sotos 2 2 - -
194050/609757 Williams-Beuren 14 6 7 1
183600 Split-Hand/Foot Malformation 1 2 2 - -
610253 Kleefstra 4 4 - -
194072 WAGR 1 1 - -
176270/105830 Prader-Willi/Angelman 19 10 7 2
612001 15q13.3 $ 26 26 - -
613406/613406 15q24 2 2 - -
* 15q26 1 1 - -
141750 ATR-16 2 2 - -
** 16p13.11 $ 45 13 32 -
136570 16p12.1 $ 24 24 - -
613444 Distal 16p11.2 $ 8 8 - -
611913 Proximal 16p11.2 $ 60 35 24 1
247200 Miller-Dieker 9 4 ^ 5 ^ -
118220/162500 Charcot-Marie-Tooth/Neuropathy, Hereditary, With Liability To Pressure Palsies 7 4 3 -
182290/610883 Smith-Magenis/17p11.2 10 8 2 -
613675 17q11.2 4 4 - -
137920 Renal Cysts And Diabetes 10 10 - -
610443/613533 17q21.31 3 2 1 -
115470 Cat-Eye 1 - 1 ^ -
188400/192430/608363 22q11.2 83 64 19 -
611867 Distal 22q11.2 9 2 7 -
606232 Phelan-Mcdermid 8 8 - -
308100 X-linked Ichthyosis 11 11 ^^ - -
312080 Pelizaeus-Merzbacher 1 - - 1
312750/300260 Rett/MECP2 2 - 2 ^^^ -
$ Susceptibility locus / incomplete penetrance.
* Tatton-Brown (2009). 15q overgrowth syndrome: a newly recognized phenotype associated with overgrowth, learning difficulties, characteristic facial
appearance, renal anomalies and increased dosage of distal chromosome 15q. Am J Med Genet 149:147.
** Hanner (2009). Recurrent reciprocal deletions and duplications of 16p13.11: the deletion is a risk factor for MR/MCA while the duplication may be a rare benign
variant. J Med Genet 46:223.
^ This patient was mosaic.
^^ all cases were x0 copy nullisomy in males.
^^^ all cases were x2 copies duplication in males.
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imbalance, karyotype or FISH analysis of the parents is
also necessary to exclude a balanced insertional trans-
location, the presence of which would carry an approxi-
mately 50% risk for the parents in future pregnancies.Nowakowska et al. [11] report a frequency of approxi-
mately 2.1% of insertional translocation among families
of patients with apparently de novo CNVs. In our ex-
perience, parental samples for chromosome rearrange-
ment studies are rarely provided; we were able to
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with apparently de novo findings, and found one paren-
tal insertional translocation.
Incidental findings
These are unavoidable for any whole genome test and
can be difficult to deal with clinically, especially with late
onset conditions and cancer-susceptibility genes where
little may be known of the prevalence or penetrance of
clinical features associated with imbalances. In collabor-
ation with our clinical oncology colleagues, we identified
58 genes, imbalance for which was considered likely,
based on published studies, to confer increased risk of
malignancy [12]. 80 patients in the cohort reported here
had imbalance for one of these genes; these imbalances
were reported with a recommendation for family studies
and genetic counselling. In addition, we have chosen to
highlight any other incidental findings where there is a
possibility that they may have a significant impact on the
health of a patient.
Balanced rearrangements
Despite the increase in resolution and the higher diagnostic
yield associated with aCGH testing, there may be concern
that without visualisation of chromosomes by traditional
cytogenetic techniques, balanced rearrangements will not
be detected. These rearrangements may disrupt gene func-
tion without causing any loss of coding material, and hence
may be important diagnostically. However, the prevalence
of de novo apparently balanced rearrangements associated
with abnormal phenotype detected by G-banded chromo-
some analysis is very low, and some of these may in fact be
unbalanced at the submicroscopic level; aCGH testing may
reveal this imbalance without the need for karyotype
analysis first. The increase in diagnostic yield by the
use of aCGH remains of far greater patient benefit than
the extremely small number of cases where a balanced
rearrangement may disrupt an important gene. Whether
in a state-funded or private service, the additional benefit
of traditional banded chromosome analysis in addition to
aCGH testing is likely to be extremely marginal.
Summary
This report describes 8,794 first line aCGH tests in a state-
funded diagnostic laboratory. To our knowledge, this is the
largest cohort of patients to date to be reported using this
approach, and the results demonstrate that aCGH is a
robust and cost-effective alternative to G-banded karyotype
analysis, and provides a higher diagnostic detection rate.
Implementation of a patient vs patient hybridisation strat-
egy reduces costs, allowing more widespread testing, and
therefore adding to the sum of information and under-
standing of the role of genomic imbalance in disease.Experience of the challenges in interpretation and
reporting of aCGH results will inform the implementa-
tion into clinical diagnostic service of higher resolution
technologies such as whole exome and whole genome
sequencing.
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